D3 Bio Unveils Breakthrough First‑Line Results for ELISRASIB at ASCO 2026
Groundbreaking First‑Line Combo Shows Promise for PD‑L1‑Positive Lung Cancer
iPAX‑2 Trial of TLX101 in First‑Line Glioblastoma Hits Full Enrollment and Dosing Confirmation